Literature DB >> 25915438

Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting.

Brenden Joseph1, Thomas Kerr1,2, Cathy M Puskas1,3, Julio Montaner1,2, Evan Wood1,2, M-J Milloy1,2.   

Abstract

HIV-positive people who use illicit drugs typically achieve lower levels of adherence to antiretroviral therapy and experience higher rates of sub-optimal HIV/AIDS treatment outcomes. Given the dearth of longitudinal research into ART adherence dynamics, we sought to identify factors associated with transitioning into and out of optimal adherence to ART in a longitudinal study of HIV-infected people who use illicit drugs (PWUD) in a setting of universal no-cost HIV/AIDS treatment. Using data from a prospective cohort of community-recruited HIV-positive illicit drug users confidentially linked to comprehensive HIV/AIDS treatment records, we estimated longitudinal factors associated with losing or gaining ≥95% adherence in the previous six months using two generalized linear mixed-effects models. Among 703 HIV-infected ART-exposed PWUD, becoming non-adherent was associated with periods of homelessness (adjusted odds ratio [AOR] = 2.52, 95% confidence interval [95% CI]: 1.56-4.07), active injection drug use (AOR = 1.25, 95% CI: 1.01-1.56) and incarceration (AOR = 1.54, 95% CI: 1.10-2.17). Periods of sex work (AOR = 0.51, 95% CI: 0.34-0.75) and injection drug use (AOR = 0.62, 95% CI: 0.50-0.77) were barriers to becoming optimally adherent. Methadone maintenance therapy was associated with becoming optimally adherent (AOR = 1.87, 95% CI: 1.50-2.33) and was protective against becoming non-adherent (AOR = 0.52, 95% CI: 0.41-0.65). In conclusion, we identified several behavioural, social and structural factors that shape adherence patterns among PWUD. Our findings highlight the need to consider these contextual factors in interventions that support the effective delivery of ART to this population.

Entities:  

Keywords:  adherence; antiretroviral therapy; drug users; incarceration; methadone; sex work

Mesh:

Year:  2015        PMID: 25915438      PMCID: PMC4830351          DOI: 10.1080/09540121.2015.1032205

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  53 in total

1.  Needle exchange is not enough: lessons from the Vancouver injecting drug use study.

Authors:  S A Strathdee; D M Patrick; S L Currie; P G Cornelisse; M L Rekart; J S Montaner; M T Schechter; M V O'Shaughnessy
Journal:  AIDS       Date:  1997-07       Impact factor: 4.177

2.  A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV.

Authors:  Robert Grossberg; Yawei Zhang; Robert Gross
Journal:  J Clin Epidemiol       Date:  2004-10       Impact factor: 6.437

3.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

4.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.

Authors:  B Ledergerber; M Egger; M Opravil; A Telenti; B Hirschel; M Battegay; P Vernazza; P Sudre; M Flepp; H Furrer; P Francioli; R Weber
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

5.  Barriers to health and social services for street-based sex workers.

Authors:  Steven P Kurtz; Hilary L Surratt; Marion C Kiley; James A Inciardi
Journal:  J Health Care Poor Underserved       Date:  2005-05

6.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

7.  Barriers to use of free antiretroviral therapy in injection drug users.

Authors:  S A Strathdee; A Palepu; P G Cornelisse; B Yip; M V O'Shaughnessy; J S Montaner; M T Schechter; R S Hogg
Journal:  JAMA       Date:  1998-08-12       Impact factor: 56.272

8.  Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users.

Authors:  Evan Wood; Julio S G Montaner; Benita Yip; Mark W Tyndall; Martin T Schechter; Michael V O'Shaughnessy; Robert S Hogg
Journal:  Antivir Ther       Date:  2004-04

9.  Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone.

Authors:  R Weber; B Ledergerber; M Opravil; W Siegenthaler; R Lüthy
Journal:  BMJ       Date:  1990-12-15

10.  Methadone dose and heroin use during maintenance treatment.

Authors:  J R Caplehorn; J Bell; D G Kleinbaum; V J Gebski
Journal:  Addiction       Date:  1993-01       Impact factor: 6.526

View more
  17 in total

Review 1.  HIV treatment cascade in MSM, people who inject drugs, and sex workers.

Authors:  Kathryn Risher; Kenneth H Mayer; Chris Beyrer
Journal:  Curr Opin HIV AIDS       Date:  2015-11       Impact factor: 4.283

2.  Identifying, linking, and treating people who inject drugs and were recently infected with HIV in the context of a network-based intervention.

Authors:  Mina Psichogiou; George Giallouros; Katerina Pantavou; Eirini Pavlitina; Martha Papadopoulou; Leslie D Williams; Andria Hadjikou; Eleni Kakalou; Athanasios Skoutelis; Konstantinos Protopapas; Anastasia Antoniadou; George Boulmetis; Dimitrios Paraskevis; Angelos Hatzakis; Samuel R Friedman; Georgios K Nikolopoulos
Journal:  AIDS Care       Date:  2019-04-02

3.  Criminal Justice System Involvement as a Risk Factor for Detectable Plasma HIV Viral Load in People Who Use Illicit Drugs: A Longitudinal Cohort Study.

Authors:  Sarah Ickowicz; N A Mohd Salleh; Nadia Fairbairn; Lindsey Richardson; Will Small; M-J Milloy
Journal:  AIDS Behav       Date:  2019-09

4.  Antiretroviral Therapy Interruption Among HIV Postive People Who Use Drugs in a Setting with a Community-Wide HIV Treatment-as-Prevention Initiative.

Authors:  Ryan McNeil; Thomas Kerr; Bill Coleman; Lisa Maher; M J Milloy; Will Small
Journal:  AIDS Behav       Date:  2017-02

5.  Treatment of opioid use disorder in an innovative community-based setting after multiple treatment attempts in a woman with untreated HIV.

Authors:  Pauline Voon; Ronald Joe; Christopher Fairgrieve; Keith Ahamad
Journal:  BMJ Case Rep       Date:  2016-07-11

Review 6.  Substance Use and Adherence to Antiretroviral Therapy: What Is Known and What Is Unknown.

Authors:  M Eugenia Socias; M-J Milloy
Journal:  Curr Infect Dis Rep       Date:  2018-07-31       Impact factor: 3.725

7.  Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam.

Authors:  Junko Tanuma; Shoko Matsumoto; Sebastien Haneuse; Do Duy Cuong; Tuong Van Vu; Pham Thi Thanh Thuy; Nguyen Thi Dung; Nguyen Thi Hoai Dung; Nguyen Vu Trung; Nguyen Van Kinh; Shinichi Oka
Journal:  J Int AIDS Soc       Date:  2017-12       Impact factor: 5.396

8.  The Impact of Substance Use on Adherence to Antiretroviral Therapy Among HIV-Infected Women in the United States.

Authors:  Yuehan Zhang; Tracey E Wilson; Adebola Adedimeji; Daniel Merenstein; Joel Milam; Jennifer Cohen; Mardge Cohen; Elizabeth T Golub
Journal:  AIDS Behav       Date:  2018-03

9.  Prevalence and Correlates of Reporting Difficulty Taking Antiretroviral Treatment Among HIV-Positive Illicit Drug Users in Vancouver, Canada: A Longitudinal Analysis.

Authors:  Bianca Yeung; N A Mohd Salleh; Eugenia Socías; Huiru Dong; J Shoveller; J S G Montaner; M-J S Milloy
Journal:  AIDS Behav       Date:  2019-05

Review 10.  Reducing rates of preventable HIV/AIDS-associated mortality among people living with HIV who inject drugs.

Authors:  Surita Parashar; Alexandra B Collins; Julio S G Montaner; Robert S Hogg; Michael-John Milloy
Journal:  Curr Opin HIV AIDS       Date:  2016-09       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.